English court gives Mylan green-light to sell generic insomnia drug
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 September 2026 Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
